Icos MAb Hu23F2G will be studied in five Phase II trials; hemorrhagic shock trial commenced in April.
ICOS MAb Hu23F2G CLINICAL PROGRAM TO INCLUDE FIVE PHASE II TRIALS, the company indicates in a prospectus for a recent public offering. The Icos development program focuses on "early acquisition of Phase II data" through "numerous appropriate Phase II clinical trials in order to increase the likelihood of identifying clinically relevant programs," the prospectus states.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth